Open AccessPercutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non‐small cell lung cancer
Author(s) -
Liu Baodong,
Liu Lei,
Hu Mu,
Qian Kun,
Li Yuanbo
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12200
Subject(s) - medicine , percutaneous , radiofrequency ablation , stage (stratigraphy) , surgery , lung cancer , confidence interval , incidence (geometry) , retrospective cohort study , survival rate , ablation , paleontology , physics , optics , biology
Background A retrospective evaluation of percutaneous radiofrequency ablation ( RFA) in medically inoperable patients with clinical stage I non‐small cell lung cancer ( NSCLC) . Methods Between 2008 and 2014, 29 medically inoperable patients with clinical stage I NSCLC underwent percutaneous RFA . We evaluated the feasibility, safety, and effectiveness. Results There were 18 men and 11 women with a median age of 78.0 years (range 56–85), mean 76.0 years. No procedure‐related deaths occurred in any of the 33 ablation procedures. The mean follow‐up was 25 months. The incidence of local tumor progression was 21.0% at 25 months of median time to progression after the initial RFA . The mean overall survival ( OS) was 57 months (95% confidence interval ( CI) 44–70 months). The mean cancer‐specific survival CSS was 63 months (95% CI 50–75 months). OS was 90.5% ± 6.4% at one year, 76.4% ± 10.7% at two, and 65.5% ± 13.6% at three years. CSS was 95.2% ± 4.6% at one, 86.6% ± 9.3% at two, and 74.2% ± 13.9% at three years in all patients. The survival for stage IA and IB cancers were 87.5% and 92.3% at one, 87.5% and 73.4% at two, and 87.5% and 58.7% at three years, respectively. Survival rates were not significantly different between the two groups ( P = 0.596), with mean survival times of 65 (95% CI : 51–79 months) and 55 months (95% CI : 38–71 months), respectively. Conclusion Percutaneous RFA is a safe, feasible, and effective procedure in medically inoperable clinical stage I NSCLC patients.